Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

N/A Completed NCT03696797

Condition	Iron, Diabetes, Nonalcoholic Fatty Liver
Phase	N/A
Sponsor	Wake Forest University Health Sciences
Status	Completed
Enrollment	132 participants
Interventions	Blood Donation, Sham Blood Donation
Start date	May 3, 2019
Completion date	Jan 3, 2025
Results posted	Jun 9, 2026

Summary

This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease.

HgbA1c Value

Baseline · percentage of HgbA1c

Treatment Group	6.31 ± 0.75 percentage of HgbA1c
Control Group	6.22 ± 0.57 percentage of HgbA1c

HgbA1c Value

month 6 · percentage of HgbA1c

Treatment Group	6.43 ± 0.77 percentage of HgbA1c
Control Group	6.32 ± 0.56 percentage of HgbA1c

ALT (Alanine Aminotransferase) Value

Baseline · IU/L

Treatment Group	25.5 ± 15.7 IU/L
Control Group	24.1 ± 12.0 IU/L

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский